Photopheresis Products Market Key Drivers, On-going Trends and Future Forecast During 2018-2026
Photopheresis
is a form of apheresis and photodynamic therapy in which blood is
treated with photosensitizing agents and irradiated with specific
wavelengths of light. It is also known as extracorporeal
photopheresis (ECP). ECP is leukapheresis based therapeutic procedure
approved by the U.S. Food and Drug Administration for treatment of
advance cutaneous T-cell lymphoma. Additionally, ECP is used in
treating disorders like graft versus host disease (GVHD), atopic
dermatitis, scleroderma, lichen planus, lupus erythematosus, Crohn’s
disease, type 1 diabetes. Many photopheresis products like open and
closed systems are available in the market, of which, only closed
system is approved by the U.S. FDA, because of its lower risk of
contamination and infection during reinfusion. Furthermore, closed
systems are technologically advanced systems in comparison to open
systems.
Photopheresis
Products Market Drivers
Rise in prevalence
of autoimmune diseases and increase in number of organ transplant
cases is expected to lead to growth of the photopheresis products
market. Increasing reimbursement policies by governments also expect
to boost the photopheresis product market. For instance, in August
2016, Mallinckrodt Pharmaceuticals, a leading specialty
pharmaceutical company, announced that Switzerland’s Federal
Department of Home Affairs (FDHA) approved the reimbursement of ECP
treatment for patients in Switzerland.
Furthermore,
business strategies such as collaborations by key players in the
photopheresis field, helps to improve the understanding of
photopheresis’ effect on immune modulations across several severe
and critical conditions. For instance, on February 2019, Mallinckrodt
plc. announced the research collaboration agreement with Transimmune
AG, a company developing novel immunotherapies, for the development
of the activation of antigen presenting cells. Both companies intend
to explore the next generation Mallinckodt photopheresis system.
However, lack of
photopheresis treatment centers, high cost and product recalls
involved in the therapy may restrain the growth of photopheresis
products market. For instance, according to report published by
American Society of Hematology in 2017, the number of chronic graft
versus host disease (cGVHD) patients increased from 16 in 2009 to 100
in 2016 and ECP use increased from 31.3% in 2009 to 54% in 2016 in
the U.S. The total annual cost per patient was US$ 190,148 including
US$ 4619 for emergency room visits, and US$ 176,856 for
hospitalization during follow up period.
Moreover, on April
5, 2016, photopheresis product, THERAKOS CELLEX, was recalled by the
manufacturer Mallinckrodt (Therakos) because the post-marketing
monitoring process detected an increasing trend in tubing leaks
within the pump tubing organizer.
Request For
Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/2653
Photopheresis
Products Market - Regional Insights
On the basis of
region, the global photopheresis products market is segmented into
North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa. North America holds a dominant position in the global
photopheresis products market as its government provides the
reimbursements for various treatments like GVHD, cytotoxic
T-lymphocytes and lung transplantation treated by ECP therapy are the
factors accountable for growth of the market. According to Leukemia
and Lymphoma society, in 2017, 30-70% people suffer from cGVHD.
Moreover, frequent approvals by regulatory bodies by European
commission for photophoresis products are expected to drive the
market. For instance, in August 2016, Swiss regulators approved the
reimbursement of Mallinckrodt plc.’s ECP treatment for patients
suffering from bronchiolitis obliterans syndrome (BOS), following a
lung transplant.
Photopheresis
Products Market - Competitive Landscape
Some of the key
players operating in the global photopheresis products market include
Macopharma, Fresenuis Kabi AG, Haemonetics Corporation, Terumo
Corporation, Dover Medical, Med Tech Solutions GmbH, and Mallinckrodt
Pharmaceuticals.
Photopheresis
Products Market - Market Taxonomy
On the basis of
product type, the global photopheresis products market is segmented
into:
Open System
Closed System
On the basis of
application, the global photopheresis products market is segmented
into:
Graft versus
Host Disease
Cutaneous T-Cell
Lymphoma
Transplant
Rejections
Autoimmune
Diseases
On the basis of end
user, the global photopheresis products market is segmented into:
Hospitals
Specialty
Clinics
Ambulatory
Surgical Centers
On the basis of
region, the global photopheresis products market is segmented into:
North America
Latin America
Europe
Asia Pacific
Middle East
Africa
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment